Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

BCOR mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

BCOR mutation	Acute Myelogenous Leukemia	BCOR mutation	Acute Myelogenous Leukemia	azacitidine Resistant: B - Late Trials azacitidine Resistant : B	azacitidine Resistant: B - Late Trials azacitidine Resistant : B
BCOR mutation	Acute Myelogenous Leukemia	BCOR mutation	Acute Myelogenous Leukemia	LY3009120 Sensitive: C3 – Early Trials LY3009120 Sensitive : C3	LY3009120 Sensitive: C3 – Early Trials LY3009120 Sensitive : C3
BCOR mutation	Acute Myelogenous Leukemia	BCOR mutation	Acute Myelogenous Leukemia	cytarabine Resistant: C3 – Early Trials cytarabine Resistant : C3	cytarabine Resistant: C3 – Early Trials cytarabine Resistant : C3
BCOR mutation	Non Small Cell Lung Cancer	BCOR mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
BCOR mutation	Acute Myelogenous Leukemia	BCOR mutation	Acute Myelogenous Leukemia	HAG + azacitidine Sensitive: C3 – Early Trials HAG + azacitidine Sensitive : C3	HAG + azacitidine Sensitive: C3 – Early Trials HAG + azacitidine Sensitive : C3
BCOR mutation	Gastrointestinal Cancer	BCOR mutation	Gastrointestinal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3